Close Menu

NEW YORK (GenomeWeb) – Abbott has no basis to elude closing its pending acquisition of Alere, the Waltham, Massachusetts-based diagnostics firm claimed after Abbott said Alere's filing of its Form 10-K for 2015 did not eliminate some concerns it had about the deal.

"In response to the statements made by an Abbott spokesman yesterday, while Abbott is free to express concerns about anything it wants, it should not imply that Abbott has any basis to avoid closing the merger, as there is absolutely no basis whatsoever for Abbott to do so," Alere said in a statement to GenomeWeb.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.